Peptidylarginine Deiminase 2 in Host Immunity: Current Insights and Perspectives

Zhenyu Wu, Patrick Li, Yuzi Tian, Wenlu Ouyang, Jessie Wai Yan Ho, Hasan B. Alam, Yongqing Li*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Peptidylarginine deiminases (PADs) are a group of enzymes that catalyze post-translational modifications of proteins by converting arginine residues into citrullines. Among the five members of the PAD family, PAD2 and PAD4 are the most frequently studied because of their abundant expression in immune cells. An increasing number of studies have identified PAD2 as an essential factor in the pathogenesis of many diseases. The successes of preclinical research targeting PAD2 highlights the therapeutic potential of PAD2 inhibition, particularly in sepsis and autoimmune diseases. However, the underlying mechanisms by which PAD2 mediates host immunity remain largely unknown. In this review, we will discuss the role of PAD2 in different types of cell death signaling pathways and the related immune disorders contrasted with functions of PAD4, providing novel therapeutic strategies for PAD2-associated pathology.

Original languageEnglish (US)
Article number761946
JournalFrontiers in immunology
StatePublished - Nov 4 2021


  • NETosis
  • PAD2
  • autoimmune diseases
  • pyroptosis
  • sepsis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Peptidylarginine Deiminase 2 in Host Immunity: Current Insights and Perspectives'. Together they form a unique fingerprint.

Cite this